183 related articles for article (PubMed ID: 12633149)
1. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy.
Brewer GJ; Hedera P; Kluin KJ; Carlson M; Askari F; Dick RB; Sitterly J; Fink JK
Arch Neurol; 2003 Mar; 60(3):379-85. PubMed ID: 12633149
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.
Brewer GJ; Johnson V; Dick RD; Kluin KJ; Fink JK; Brunberg JA
Arch Neurol; 1996 Oct; 53(10):1017-25. PubMed ID: 8859064
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.
Brewer GJ; Dick RD; Johnson V; Wang Y; Yuzbasiyan-Gurkan V; Kluin K; Fink JK; Aisen A
Arch Neurol; 1994 Jun; 51(6):545-54. PubMed ID: 8198464
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
[TBL] [Abstract][Full Text] [Related]
6. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
Brewer GJ
CNS Drugs; 2005; 19(3):185-92. PubMed ID: 15740174
[TBL] [Abstract][Full Text] [Related]
7. Penicillamine-related neurologic syndrome in a child affected by Wilson disease with hepatic presentation.
Porzio S; Iorio R; Vajro P; Pensati P; Vegnente A
Arch Neurol; 1997 Sep; 54(9):1166-8. PubMed ID: 9311362
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of neurologic examination findings in Wilson disease.
Burke JF; Dayalu P; Nan B; Askari F; Brewer GJ; Lorincz MT
Parkinsonism Relat Disord; 2011 Aug; 17(7):551-6. PubMed ID: 21641265
[TBL] [Abstract][Full Text] [Related]
9. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
Esmaeli B; Burnstine MA; Martonyi CL; Sugar A; Johnson V; Brewer GJ
Cornea; 1996 Nov; 15(6):582-8. PubMed ID: 8899270
[TBL] [Abstract][Full Text] [Related]
10. Early neurological worsening in patients with Wilson's disease.
Litwin T; Dzieżyc K; Karliński M; Chabik G; Czepiel W; Członkowska A
J Neurol Sci; 2015 Aug; 355(1-2):162-7. PubMed ID: 26071888
[TBL] [Abstract][Full Text] [Related]
11. Adverse reaction after tetrathiomolybdate treatment for Wilson's disease: a case report.
Medici V; Trevisan CP; Bigotto MA; D'Incà R; Martines D; Dal Pont E; Sturniolo GC
Mov Disord; 2006 Nov; 21(11):2030-2. PubMed ID: 16991142
[No Abstract] [Full Text] [Related]
12. Initial therapy of patients with Wilson's disease with tetrathiomolybdate.
Brewer GJ; Dick RD; Yuzbasiyan-Gurkin V; Tankanow R; Young AB; Kluin KJ
Arch Neurol; 1991 Jan; 48(1):42-7. PubMed ID: 1986725
[TBL] [Abstract][Full Text] [Related]
13. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
Brewer GJ
Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
[TBL] [Abstract][Full Text] [Related]
14. Development of neurologic symptoms in a patient with asymptomatic Wilson's disease treated with penicillamine.
Brewer GJ; Turkay A; Yuzbaziyan-Gurkan V
Arch Neurol; 1994 Mar; 51(3):304-5. PubMed ID: 8129644
[TBL] [Abstract][Full Text] [Related]
15. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
16. Wilson disease - currently used anticopper therapy.
Członkowska A; Litwin T
Handb Clin Neurol; 2017; 142():181-191. PubMed ID: 28433101
[TBL] [Abstract][Full Text] [Related]
17. [Wilson disease: an update].
Seo JK
Korean J Hepatol; 2006 Sep; 12(3):333-63. PubMed ID: 16998287
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
19. Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients.
Linn FH; Houwen RH; van Hattum J; van der Kleij S; van Erpecum KJ
Hepatology; 2009 Nov; 50(5):1442-52. PubMed ID: 19731238
[TBL] [Abstract][Full Text] [Related]
20. [Advances in the treatment of Wilson Disease].
Xiao QQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):79-82. PubMed ID: 33541028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
